Yousif Capital Management LLC Increases Position in IQVIA Holdings Inc. (NYSE:IQV)

Yousif Capital Management LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 7.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 31,129 shares of the medical research company’s stock after acquiring an additional 2,110 shares during the quarter. Yousif Capital Management LLC’s holdings in IQVIA were worth $6,378,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wedmont Private Capital boosted its stake in shares of IQVIA by 28.7% in the 4th quarter. Wedmont Private Capital now owns 1,842 shares of the medical research company’s stock worth $378,000 after buying an additional 411 shares during the last quarter. Symmetry Partners LLC raised its holdings in IQVIA by 14.8% during the 4th quarter. Symmetry Partners LLC now owns 2,244 shares of the medical research company’s stock valued at $460,000 after acquiring an additional 290 shares during the period. General Partner Inc. bought a new stake in IQVIA during the 4th quarter valued at $90,000. Centaurus Financial Inc. bought a new position in shares of IQVIA in the third quarter worth $403,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in shares of IQVIA by 4.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 349,061 shares of the medical research company’s stock worth $63,227,000 after purchasing an additional 14,717 shares during the period. Hedge funds and other institutional investors own 86.20% of the company’s stock.

Insiders Place Their Bets

In other news, insider Kevin C. Knightly sold 4,446 shares of the stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the completion of the transaction, the insider now directly owns 1,973 shares in the company, valued at approximately $445,128.53. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the sale, the insider now directly owns 17,053 shares of the company’s stock, valued at $3,922,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin C. Knightly sold 4,446 shares of the firm’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $225.61, for a total value of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares in the company, valued at $445,128.53. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have issued reports on IQV. Credit Suisse Group restated an “outperform” rating and set a $265.00 price target on shares of IQVIA in a research report on Monday, February 13th. Robert W. Baird cut their price target on shares of IQVIA from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Friday, January 13th. Truist Financial began coverage on shares of IQVIA in a report on Friday. They issued a “buy” rating and a $265.00 target price on the stock. Cowen began coverage on shares of IQVIA in a report on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 target price on the stock. Finally, StockNews.com started coverage on shares of IQVIA in a research note on Thursday. They set a “hold” rating on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $256.81.

IQVIA Price Performance

IQVIA stock opened at $190.89 on Friday. The firm has a market capitalization of $35.53 billion, a PE ratio of 33.43, a P/E/G ratio of 1.97 and a beta of 1.40. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 2.18. The firm’s 50-day simple moving average is $218.94 and its 200 day simple moving average is $208.72. IQVIA Holdings Inc. has a 52 week low of $165.75 and a 52 week high of $254.94.

IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings data on Friday, February 10th. The medical research company reported $2.78 EPS for the quarter, beating analysts’ consensus estimates of $2.76 by $0.02. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.71 billion. IQVIA had a net margin of 7.57% and a return on equity of 31.88%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.42 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 9.46 EPS for the current fiscal year.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.